Histone modifications

Implications in renal cell carcinoma

Swathi Ramakrishnan, Leigh Ellis, Roberto Pili

Research output: Contribution to journalArticle

Abstract

In 2012, an estimated 64,770 men and women were diagnosed with malignancy of the kidney and renal pelvis, of which 13,570 succumbed to their disease. Common genetic aberrations in renal cell carcinomas (RCCs) include loss of function of the VHL gene in clear-cell RCC, overexpression of the c-MET gene in papillary RCC type I, deficiency in the FH gene in papillary RCC type II and loss of heterozygozity of the BHD gene in chromophobe RCC. Recent studies illustrate epigenetic silencing of VHL, as well as alterations in histone modifications and their governing enzymes. The possibility of reversing these epigenetic marks has resulted in efforts to target these changes by utilizing inhibitors of HDACs, DNA methyltransferases and, recently, histone methyltransferases in preclinical and clinical studies. This article focuses on potential therapeutic interventions, and the implications of histone modifications and related enzyme alterations in RCC.

Original languageEnglish (US)
Pages (from-to)453-462
Number of pages10
JournalEpigenomics
Volume5
Issue number4
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Histone Code
Renal Cell Carcinoma
Kidney Pelvis
Epigenomics
Genes
Histone Deacetylase Inhibitors
Methyltransferases
Enzymes
DNA

Keywords

  • DNA methyltransferase
  • epigenetics
  • HDAC
  • histone acetylation
  • histone methylation
  • renal cell carcinoma

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

Histone modifications : Implications in renal cell carcinoma. / Ramakrishnan, Swathi; Ellis, Leigh; Pili, Roberto.

In: Epigenomics, Vol. 5, No. 4, 08.2013, p. 453-462.

Research output: Contribution to journalArticle

Ramakrishnan, S, Ellis, L & Pili, R 2013, 'Histone modifications: Implications in renal cell carcinoma', Epigenomics, vol. 5, no. 4, pp. 453-462. https://doi.org/10.2217/epi.13.40
Ramakrishnan, Swathi ; Ellis, Leigh ; Pili, Roberto. / Histone modifications : Implications in renal cell carcinoma. In: Epigenomics. 2013 ; Vol. 5, No. 4. pp. 453-462.
@article{795f72a9b44046318e1058ab3b2e2951,
title = "Histone modifications: Implications in renal cell carcinoma",
abstract = "In 2012, an estimated 64,770 men and women were diagnosed with malignancy of the kidney and renal pelvis, of which 13,570 succumbed to their disease. Common genetic aberrations in renal cell carcinomas (RCCs) include loss of function of the VHL gene in clear-cell RCC, overexpression of the c-MET gene in papillary RCC type I, deficiency in the FH gene in papillary RCC type II and loss of heterozygozity of the BHD gene in chromophobe RCC. Recent studies illustrate epigenetic silencing of VHL, as well as alterations in histone modifications and their governing enzymes. The possibility of reversing these epigenetic marks has resulted in efforts to target these changes by utilizing inhibitors of HDACs, DNA methyltransferases and, recently, histone methyltransferases in preclinical and clinical studies. This article focuses on potential therapeutic interventions, and the implications of histone modifications and related enzyme alterations in RCC.",
keywords = "DNA methyltransferase, epigenetics, HDAC, histone acetylation, histone methylation, renal cell carcinoma",
author = "Swathi Ramakrishnan and Leigh Ellis and Roberto Pili",
year = "2013",
month = "8",
doi = "10.2217/epi.13.40",
language = "English (US)",
volume = "5",
pages = "453--462",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Histone modifications

T2 - Implications in renal cell carcinoma

AU - Ramakrishnan, Swathi

AU - Ellis, Leigh

AU - Pili, Roberto

PY - 2013/8

Y1 - 2013/8

N2 - In 2012, an estimated 64,770 men and women were diagnosed with malignancy of the kidney and renal pelvis, of which 13,570 succumbed to their disease. Common genetic aberrations in renal cell carcinomas (RCCs) include loss of function of the VHL gene in clear-cell RCC, overexpression of the c-MET gene in papillary RCC type I, deficiency in the FH gene in papillary RCC type II and loss of heterozygozity of the BHD gene in chromophobe RCC. Recent studies illustrate epigenetic silencing of VHL, as well as alterations in histone modifications and their governing enzymes. The possibility of reversing these epigenetic marks has resulted in efforts to target these changes by utilizing inhibitors of HDACs, DNA methyltransferases and, recently, histone methyltransferases in preclinical and clinical studies. This article focuses on potential therapeutic interventions, and the implications of histone modifications and related enzyme alterations in RCC.

AB - In 2012, an estimated 64,770 men and women were diagnosed with malignancy of the kidney and renal pelvis, of which 13,570 succumbed to their disease. Common genetic aberrations in renal cell carcinomas (RCCs) include loss of function of the VHL gene in clear-cell RCC, overexpression of the c-MET gene in papillary RCC type I, deficiency in the FH gene in papillary RCC type II and loss of heterozygozity of the BHD gene in chromophobe RCC. Recent studies illustrate epigenetic silencing of VHL, as well as alterations in histone modifications and their governing enzymes. The possibility of reversing these epigenetic marks has resulted in efforts to target these changes by utilizing inhibitors of HDACs, DNA methyltransferases and, recently, histone methyltransferases in preclinical and clinical studies. This article focuses on potential therapeutic interventions, and the implications of histone modifications and related enzyme alterations in RCC.

KW - DNA methyltransferase

KW - epigenetics

KW - HDAC

KW - histone acetylation

KW - histone methylation

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84881097042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881097042&partnerID=8YFLogxK

U2 - 10.2217/epi.13.40

DO - 10.2217/epi.13.40

M3 - Article

VL - 5

SP - 453

EP - 462

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 4

ER -